 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...485486487488489490491492493494495...507508» |
- cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (clinicaltrials.gov) - Aug 7, 2014
P1, N=60, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting
- Herceptin (trastuzumab) / Roche
Enrollment closed, Adverse events: Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) (clinicaltrials.gov) - Aug 5, 2014
P3, N=1418, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide (clinicaltrials.gov) - Aug 4, 2014
P4, N=18, Recruiting, Sponsor: Texas Tech University Health Sciences Center
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Aug 2015
- || Trial primary completion date: MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (clinicaltrials.gov) - Aug 4, 2014
P4, N=226, Recruiting, Sponsor: Agendia
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Dec 2013 --> Dec 2015
- | Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy: A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma (clinicaltrials.gov) - Aug 4, 2014
P2, N=43, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Dec 2013 --> Dec 2015 N=95 --> 43
- | Votrient (pazopanib) / Novartis, BeiGene
New P2 trial: Pazopanib Maintenance Phase II (clinicaltrials.gov) - Aug 4, 2014
P2, N=150, Not yet recruiting, Sponsor: Ludwig-Maximilians - University of Munich
- | dexrazoxane / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma (clinicaltrials.gov) - Aug 3, 2014
P3, N=253, Completed, Sponsor: Children's Oncology Group
N=95 --> 43 No longer recruiting --> Completed
- ||||| Enrollment change: Combination Chemotherapy in Treating Children With Neuroblastoma (clinicaltrials.gov) - Aug 1, 2014
P3, N=573, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed N=400 --> 573
- |||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 1, 2014
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=400 --> 573 Active, not recruiting --> Recruiting
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment closed: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 1, 2014
P3, N=1900, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Trial completion: Combination Chemotherapy in Treating Children With Neuroblastoma (clinicaltrials.gov) - Jul 31, 2014
P3, N=573, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- Trial primary completion date: Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer (clinicaltrials.gov) - Jul 30, 2014
P1, N=24, Active, not recruiting, Sponsor: University of Utah
No longer recruiting --> Completed Trial primary completion date: Nov 2013 --> Jul 2015
- Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 30, 2014
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Nov 2013 --> Jul 2015 Trial primary completion date: Jun 2014 --> Dec 2014
- ||||| Herceptin (trastuzumab) / Roche
Trial initiation date: Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer (clinicaltrials.gov) - Jul 30, 2014
P3, N=3150, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Jun 2014 --> Dec 2014 Initiation date: Apr 2001 --> Mar 2002
- ||||| Trial initiation date, Surgery: Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors (clinicaltrials.gov) - Jul 27, 2014
P3, N=203, Completed, Sponsor: Children's Oncology Group
Initiation date: Apr 2001 --> Mar 2002 Initiation date: May 2002 --> Jan 1996
- Decadron (dexamethasone) / Merck (MSD)
Trial primary completion date: UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (clinicaltrials.gov) - Jul 26, 2014
P2, N=90, Enrolling by invitation, Sponsor: University of Arkansas
Initiation date: May 2002 --> Jan 1996 Trial primary completion date: Oct 2013 --> Oct 2015
- || cyclophosphamide / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 26, 2014
P3, N=20, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Oct 2013 --> Oct 2015 Active, not recruiting --> Completed
- |||| Trial primary completion date: TT4B: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma (clinicaltrials.gov) - Jul 25, 2014
P3, N=350, Recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2015
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (clinicaltrials.gov) - Jul 25, 2014
P2, N=24, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Sep 2014 --> Sep 2015 Recruiting --> Active, not recruiting
- | ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial completion, Surgery, Metastases: Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 25, 2014
P2, N=43, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Trial initiation date: TACE as an Adjuvant Therapy After Hepatectomy for HCC (clinicaltrials.gov) - Jul 24, 2014
P3, N=120, Enrolling by invitation, Sponsor: Jia Fan
Active, not recruiting --> Completed Initiation date: Jan 2012 --> Aug 2011
- Rituxan (rituximab) / Roche
Enrollment change, Trial termination, Trial primary completion date: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 24, 2014
P2, N=53, Terminated, Sponsor: Southwest Oncology Group
Initiation date: Jan 2012 --> Aug 2011 N=180 --> 53 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2015
- Sutent (sunitinib) / Pfizer
Enrollment change, Trial primary completion date, Metastases: Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor (clinicaltrials.gov) - Jul 24, 2014
P2, N=73, Recruiting, Sponsor: National University Hospital, Singapore
N=180 --> 53 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2015 N=50 --> 73 | Trial primary completion date: Dec 2014 --> Dec 2015
- ||||| Enrollment change, Trial initiation date: Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer (clinicaltrials.gov) - Jul 24, 2014
P3, N=3031, Completed, Sponsor: Children's Oncology Group
N=50 --> 73 | Trial primary completion date: Dec 2014 --> Dec 2015 N=207 --> 3031 | Initiation date: May 2002 --> Jul 1995
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial, Combination therapy: NCI-2014-01707: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 24, 2014
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| Opdivo (nivolumab) / BMS
Enrollment open: CheckMate 205: Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (clinicaltrials.gov) - Jul 24, 2014
P2, N=120, Recruiting, Sponsor: Bristol-Myers Squibb
N=207 --> 3031 | Initiation date: May 2002 --> Jul 1995 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial primary completion date: S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=142, Completed, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | N=320 --> 142 | Trial primary completion date: Dec 2009 --> Jun 2012
- ||||||| Trial completion, Enrollment change: CCLG-NHL-9600: TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 24, 2014
P3, N=1148, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Completed | N=320 --> 142 | Trial primary completion date: Dec 2009 --> Jun 2012 Active, not recruiting --> Completed | N=900 --> 1148
- | Trial completion, Surgery, Metastases: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma (clinicaltrials.gov) - Jul 24, 2014
P1, N=30, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=900 --> 1148 Active, not recruiting --> Completed
- ||||||| doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma (clinicaltrials.gov) - Jul 24, 2014
P3, N=242, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| thioguanine / Generic mfg.
Trial completion, Enrollment change: Combination Chemotherapy in Treating Children With Lymphoma (clinicaltrials.gov) - Jul 24, 2014
P2, N=221, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=90 --> 221
- Phase classification, Trial primary completion date, Metastases: Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=15, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | N=90 --> 221 Phase classification: P2 --> P=N/A | Trial primary completion date: Aug 2014 --> Aug 2015
- everolimus / Generic mfg.
Enrollment closed, Combination therapy: Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (clinicaltrials.gov) - Jul 23, 2014
P1, N=42, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Phase classification: P2 --> P=N/A | Trial primary completion date: Aug 2014 --> Aug 2015 Recruiting --> Active, not recruiting
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment closed, Metastases: A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) (clinicaltrials.gov) - Jul 23, 2014
P3, N=1401, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Trial completion, Surgery: Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors (clinicaltrials.gov) - Jul 23, 2014
P3, N=203, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- | dexrazoxane / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease (clinicaltrials.gov) - Jul 22, 2014
P3, N=219, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer (clinicaltrials.gov) - Jul 22, 2014
P3, N=3031, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed No longer recruiting --> Completed
- | Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Surgery: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov) - Jul 17, 2014
P2/3, N=340, Recruiting, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- veliparib (ABT-888) / AbbVie
Enrollment closed, Combination therapy, PARP Biomarker, Metastases: Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 17, 2014
P1, N=90, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents (clinicaltrials.gov) - Jul 16, 2014
P1, N=12, Recruiting, Sponsor: Presage Biosciences
Recruiting --> Active, not recruiting Trial primary completion date: May 2014 --> Nov 2015
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
New P2 trial: Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma (clinicaltrials.gov) - Jul 16, 2014
P2, N=70, Not yet recruiting, Sponsor: University of Cologne
- doxorubicin hydrochloride / Generic mfg.
New P1 trial: Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) (clinicaltrials.gov) - Jul 16, 2014
P1, N=54, Not yet recruiting, Sponsor: University of Pittsburgh
- ||||||| zoledronic acid / Generic mfg.
Trial completion, Metastases: NEO-ZOTAC: Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients (clinicaltrials.gov) - Jul 16, 2014
P3, N=250, Completed, Sponsor: Borstkanker Onderzoek Groep
Trial primary completion date: May 2014 --> Nov 2015 Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer (clinicaltrials.gov) - Jul 16, 2014
P2, N=60, Completed, Sponsor: William Sikov
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2014
- bortezomib / Generic mfg.
Trial primary completion date, Combination therapy: Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 15, 2014
P2, N=17, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2014 Trial primary completion date: Mar 2014 --> Mar 2015
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Jul 15, 2014
P3, N=4808, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (clinicaltrials.gov) - Jul 14, 2014
P2, N=20, Recruiting, Sponsor: Columbia University
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2013 --> Oct 2015
- || brivanib alaninate (BMS-582664) / ZAI Lab
Trial primary completion date, Combination therapy, Metastases: Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers (clinicaltrials.gov) - Jul 14, 2014
P1, N=189, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2013 --> Oct 2015 Trial primary completion date: Mar 2014 --> Feb 2015
- ||||| veliparib (ABT-888) / AbbVie
Trial initiation date: BrighTNess: A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 14, 2014
P3, N=624, Recruiting, Sponsor: AbbVie
Trial primary completion date: Mar 2014 --> Feb 2015 Initiation date: Jan 2014 --> Apr 2014